Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
NLS Pharmaceutics Ltd. is a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies for rare and complex central nervous system (CNS) disorders. Headquartered in Zurich, Switzerland, the company leverages advanced scientific platforms, including its proprietary dual orexin receptor agonist (DOXA) technology, to target neurobehavioral and neurocognitive challenges such as narcolepsy, ADHD, and other sleep-related conditions. NLS Pharmaceutics is committed to delivering safer, more effective treatments that address significant unmet medical needs in the global CNS therapeutics market. Its pipeline includes lead candidates like Mazindol ER, designed to improve symptoms in patients with narcolepsy and ADHD, as well as other investigational assets targeting neurodegenerative diseases. The company’s research is supported by a network of world-class partners and scientists, emphasizing rigorous clinical development and robust intellectual property. In October 2025, NLS Pharmaceutics completed a strategic merger with Kadimastem Ltd., forming NewcelX Ltd., which consolidates expertise in both drug development and cell therapy to broaden its impact across neurodegenerative diseases and diabetes. This evolution positions the company at the forefront of next-generation CNS therapies, combining cutting-edge science with a patient-centric approach to drive meaningful advances in brain health.
$3.55
$0.04 (-1.11%)
EOD Jun 25, 2026 · Twelve Data
Negative free cash flow of -$3M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$0.00
Net Income (TTM)
-$8M
▼ -15.3% YoY
Op. Margin
—
ROIC
-38.06%
▲ +12.9pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$3M
▼ -158.8% YoY
Op. Cash Flow (TTM)
-$3M
▼ -146.6% YoY
Net Debt
-$2M
Net Cash Position
Cash & Equiv.
$2M
Continue Research
NLS Pharmaceutics (NCEL)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, NLS Pharmaceutics scores 10/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
NLS Pharmaceutics scores 10 out of 100 on Intrinsiqq's quality score, a weighted blend of 4 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -38.1% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh NCEL's valuation and scores 10/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.